Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

GBS Inc. (GBS)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.4700-0.0800 (-5.16%)
At close: 04:00PM EST
1.4700 0.00 (0.00%)
After hours: 07:08PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.5500
Open1.5300
Bid1.4700 x 3000
Ask1.5100 x 900
Day's Range1.4500 - 1.5300
52 Week Range1.2600 - 9.6300
Volume140,127
Avg. Volume979,491
Market Cap21.877M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Zacks Small Cap Research

    GBS: Spit it Out: Testing Without the Blood

    By John Vandermosten, CFA NASDAQ:GBS READ THE FULL GBS RESEARCH REPORT The number of diagnostic tests used to evaluate biological material has exploded over the last decades. These tests help identify disease, determine treatment and show whether or not a condition is under control among other benefits. One of the earliest conditions evaluated using diagnostic tests was diabetes. The first

  • GlobeNewswire

    GBS Inc. to Participate in the Upcoming January Virtual Investor Conferences

    NEW YORK, Dec. 20, 2021 (GLOBE NEWSWIRE) -- GBS (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced that Dr. Steven Boyages, GBS’ interim CEO and Chairman of the Board, along with other management team members will participate in the following conferences in January and invites investors to participate in virtual one-on-one meetings. Please see additional details below:

  • GlobeNewswire

    GBS Inc. Announces Application for FDA Breakthrough Device Designation to Fast Track Rapid Saliva Glucose Test

    NEW YORK, Dec. 13, 2021 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced that in collaboration with Life Science Biosensor Diagnostics Pty Ltd (LSBD), the licensor of the Rapid Saliva Glucose Test [that forms part of the Biosensor Platform licensed by GBS Inc. (GBS)], LSBD has filed an application with the U.S. Food and Drug Administration

Advertisement
Advertisement